On 18 September 2001, orphan designation EU/3/01/055 was granted by the European Commission to Lipomed GmbH, Germany, for cladribine (subcutaneous use) for the treatment of indolent non-Hodgkin's lymphoma.
Cladribine (subcutaneous use) has been authorised in the EU as Litak since 14 April 2004.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
|Disease / condition||
Treatment of indolent non-Hodgkin's lymphoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.